Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Phytotherapeutics self-microemulsifying systems in pellet dosage form for enhanced intestinal drug delivery: formulation, stability, and <i>in-vivo</i> performance.

Drug delivery·2026

Same author

Canine high-grade astrocytomas are currently distinct from human glioblastomas.

Veterinary pathology·2026

Same author

Mechanistic Exploration of Half-Sandwich Iridium(III) Anticancer Compounds through Integrated Cellular, Proteomic, and In Vivo Analyses.

Journal of medicinal chemistry·2026

Same author

An intronic variant in Ferredoxin Reductase (FDXR) creates a cryptic exon in Quarter Horses with Equine Juvenile Spinocerebellar Ataxia.

PLoS genetics·2026

Same author

Smart Pediatric Oncology Tracker of Symptoms (SPOTS), a Web-Based Interface for the Pediatric PRO-CTCAE: Development and Usability Study.

JMIR formative research·2026

Same author

Schwannosis with mature collagen in the spinal cord of a calf.

Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc·2026

Search research articles

Related Experiment Video

Updated: Mar 25, 2026

Synthesis and Characterization of Placental Chondroitin Sulfate A plCSA-Targeting Lipid-Polymer Nanoparticles

Synthesis and Characterization of Placental Chondroitin Sulfate A plCSA-Targeting Lipid-Polymer Nanoparticles

Published on: September 18, 2018

Liposomal nanocarriers for plasminogen activators.

Stepan Koudelka¹, Robert Mikulik², Josef Mašek³

¹Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Brno, Czech Republic; International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic.

Journal of Controlled Release : Official Journal of the Controlled Release Society

|February 16, 2016

Summary

Liposome formulations enhance the efficacy and safety of plasminogen activators (PAs) for treating blood clots. These advanced delivery systems improve PA targeting and reduce side effects compared to conventional therapies.

Keywords:

Fibrin Liposomes Platelets Protein delivery RGD peptide Streptokinase Stroke Thrombus Tissue plasminogen activator Urokinase

More Related Videos

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation

Published on: December 15, 2010

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications

Published on: November 17, 2015

Related Experiment Videos

Last Updated: Mar 25, 2026

Synthesis and Characterization of Placental Chondroitin Sulfate A plCSA-Targeting Lipid-Polymer Nanoparticles

Synthesis and Characterization of Placental Chondroitin Sulfate A plCSA-Targeting Lipid-Polymer Nanoparticles

Published on: September 18, 2018

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation

Published on: December 15, 2010

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications

Published on: November 17, 2015

Area of Science:

Biomedical Engineering
Pharmacology
Nanotechnology

Background:

Conventional plasminogen activators (PAs) face limitations in treating thromboembolic diseases due to low efficacy, rapid clearance, and non-specific targeting.
Current thrombolytic therapies using PAs are associated with significant side effects, including bleeding complications and immunogenicity.

Purpose of the Study:

To review advancements in liposome-based formulations of plasminogen activators (PAs) for improved thrombolytic therapy.
To evaluate the potential of liposomal PAs in enhancing therapeutic efficacy and safety for thromboembolic diseases.

Main Methods:

Preparation and characterization of various liposome-based PA formulations, including PEGylated and targeted systems.
In vivo pre-clinical testing of thrombolytic efficacy and safety profiles of liposomal PAs.
Physico-chemical characterization of developed liposomal PA systems.

Main Results:

Liposomal formulations preserve the activity of PAs while promoting selective delivery and improving thrombus targeting.
Pre-clinical studies demonstrate enhanced efficacy and safety of liposomal PAs compared to conventional formulations.
Reductions in adverse effects such as hemorrhage and immunogenicity were observed with liposomal PAs.

Conclusions:

Liposome-based plasminogen activators represent a significant improvement over conventional formulations for treating thromboembolic diseases.
Further development, including theranostic liposomal formulations, holds promise for advancing thrombolytic therapy.